GEN Exclusives

More »

GEN News Highlights

More »
Feb 11, 2009

Ferring Opens San Diego Center for Peptide Research

  • Ferring Pharmaceuticals along with its affiliate Ferring Research Institute opened a 38,000 sq. ft. facility in Sorrento Valley, San Diego that will be dedicated to peptide research and therapeutics.

    The company already has an R&D center in San Diego, and the new site will have expanded research laboratories for peptide medicinal chemistry, bioanalytical and DMPK (distribution, metabolism, and pharmacokinetics) activities, molecular and cell biology research, cell culture, as well as in vitro and in vivo pharmacology, explains Ferring.

    The company recently gained approval for its peptide-based therapeutic for hormone-dependent prostate cancer called degarelix. It was discovered by Ferring Research Institute in San Diego and will be developed globally by Ferring Pharmaceuticals. The company is preparing to launch degarelix in the U.S. in the first quarter.



    To comment on this story, go to BLOGbiotech.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »